In a diverse cohort of virologically suppressed women with HIV, long-acting cabotegravir and rilpivirine (CAB+RPV LA) maintained high rates of viral suppression with low virologic failure over a median...
Researchers determined the predictive value of urine point-of-care tenofovir antibody test and compared the results against self-reported PrEP use and TFV-diphosphate levels in dried blood spots. Their...
Researchers evaluated the impact an intensified dose of dolutegravir had on patients living with HIV. Their research was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023...
To better understand the relationship between vaccination and PASC risk in this patient population, researchers utilized the TriNetX health research database. Data from more than 3 million adults who tested...
Researchers compared pre-exposure prophylaxis (PrEP) use with birth outcomes using objective levels of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) of women during the second or third trimester...
In a new study presented at CROI 2023, researchers examined how depression and anxiety in individuals with HIV impacts the risk of incident acute myocardial infarction in this patient population.
Researchers compared the effectiveness of a COVID-19 booster vaccine dose vs full vaccination only at reducing breakthrough infections and COVID-19-related death in individuals of various immune status. ...
Newer antiretroviral therapies exert adverse cardiovascular effects. Therefore, monitoring rates of myocardial infarction by HIV status is critical. In a recent study, researchers examined the national...
In a recent study presented at CROI 2022, researchers examined how the COVID-19 pandemic affected rates of testing and diagnosis of sexually transmitted infections.
